Recently FDA-approved CDK 4/6 inhibitor, palbociclib, for treating metastatic breast cancer | Dr Richard Finn at St. Gallen Breast Cancer Conference 2015

Recently FDA-approved CDK 4/6 inhibitor, palbociclib, for treating metastatic breast cancer | Dr Richard Finn at St. Gallen Breast Cancer Conference 2015

User Photo
EMJ

5 years
2,185 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Richard Finn (UCLA, Los Angeles, CA) discusses the development of the cyclin-dependent kinases (CDKs) 4 and 6 inhibitor, palbociclib, for breast cancer treatment.

The phase 2 PALOMA-1 trial showed that the addition of palbociclib to letrozole significantly increased the progression-free survival versus letrozole alone in oestrogen receptor-positive, HER2-negative metastatic breast cancer. Subsequently, palbociclib received accelerated approval as frontline treatment for this patient population. Current trials are investigating palbociclib in other areas of breast cancer.



European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay